Results 121 to 130 of about 4,256 (179)

Associations of finerenone with reduced insulin resistance in patients with type 2 diabetes and chronic kidney disease: A real‐world observational study

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1524-1532, September 2026.
This real‐world observational study enrolled 256 patients with type 2 diabetes and chronic kidney disease (T2D‐CKD). After 12 months of finerenone treatment, 45 patients completed follow‐up. Finerenone was associated with significant improvements in insulin resistance markers (HOMA‐IR, TyG index), lipid profile (LDL‐C), glycemic control (HbA1c), and ...
Xin Zhao, Bohan Liu, Ran Sun, Yaxuan Shi, Ya Liu   +4 more
wiley   +1 more source

On the History of Hepatic Vein Catheterization

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT Hepatic vein catheterization (HVC) in man was first performed 80 years ago in the wake of right‐sided heart catheterization. Several new methods, recognitions and concepts followed, especially the indirect Fick‐method for determination of splanchnic blood flow. Five years passed before pressure measurements were performed and routine HVCs were
Jens Henrik Henriksen, Flemming Bendtsen, Søren Møller   +2 more
wiley   +1 more source

Triangulating the Skeletal Safety of SGLT2 Inhibitors in Diabetes

Journal of Diabetes, Volume 18, Issue 9, September 2026.
Bin Huang, Shujie Yu, Anran Su, Yi Zheng, Yue Teng, Wei Wang   +5 more
wiley   +1 more source

The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road? [PDF]

J Membr Biol, 2021
Liu J, Tian J, Sodhi K, Shapiro JI.
europepmc   +1 more source

A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection. [PDF]

Cureus, 2022
Raza S, Osasan S, Sethia S, Batool T, Bambhroliya Z, Sandrugu J, Lowe M, Okunlola O, Hamid P.   +8 more
europepmc   +1 more source

Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection? [PDF]

Drugs, 2021
Koufakis T, Mustafa OG, Tsimihodimos V, Ajjan RA, Kotsa K.   +4 more
europepmc   +1 more source

The Role of Finerenone in Cardiorenal Protection and Urine Albumin-to-Creatinine Ratio Modulation. [PDF]

Kidney Int Rep
Singh AK, Khan MS.
europepmc   +1 more source

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus. [PDF]

Cureus, 2021
Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange AH, Sange I.   +7 more
europepmc   +1 more source

Sodium-Glucose Cotransporter-2 Inhibitors in CKD: Is it Time to Update the Guideline Recommendations for Broader Cardiorenal Protection? [PDF]

Kidney Int Rep
Georgianos PI, Vaios V, Roumeliotis A, Liakopoulos V.   +3 more
europepmc   +1 more source

Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis. [PDF]

Clin Cardiol
Khalil I, Hossain MI, Akter MM, Wahid F, Khalid AA, Promi SA, Sayed MA, Rahman MT, Sarker P.   +8 more
europepmc   +1 more source